Anti-VPRBP/DCAF1 Antibody Picoband® (Dylight488 Conjugate)

VprBP was first identified as a protein that can interact with HIV-1 viral protein R. It is a component of the CUL4A-RBX1-DDB1-VprBP/DCAF1 E3 ubiquitin-protein ligase complex that could interact with HIV-1 virus Vpr protein and HIV-2 virus Vpx protein. VprBP is a 1,507-amino acid protein that contains conserved domains, including YXXY repeats, the Lis homology motif, and WD40 repeats. Through binding to Vpr, VprBP allows Vpr to modulate the catalytic activity of the CUL4-DDB1 complex, which in turn leads to the induction of G2 phase arrest in the virus-infected cells. Recently it has been reported that VprBP is able to regulate the p53-induced transcription and apoptotic pathway.

Could induce apoptosis in a BH3 domain-dependent manner. The interaction network of Bcl-2 family members may play a key role in modulation RTL10/BOP intrinsic apoptotic signaling activity.

At -20℃ for one year from date of receipt. After reconstitution, at 4℃ for one month. It can also be aliquotted and stored frozen at -20℃ for six months. Avoid repeated freezing and thawing.

Western blot, 0.25-0.5 μg/ml, Human<br> Immunohistochemistry(Paraffin-embedded Section), 2-5 μg/ml, Human, Mouse, Rat<br> Immunocytochemistry/Immunofluorescence, 5 μg/ml, Human<br> Flow Cytometry (Fixed), 1-3 μg/1x10⁶ cells, Human<br> ELISA, 0.1-0.5 μg/ml, -<br>